Large clinical studies such as RALES [65] and EPHESUS [66] have demonstrated the efficacy of mineralocorticoid receptor antagonism in patients with heart failure showing that low dose mineralocorticoid receptor antagonism (in addition to standard therapy) significantly reduced morbidity and mortality in heart failure with reduced ejection fraction (HFrEF) patients [65]. Here, NR3C2 is linked to heart failure.